Neoadjuvant GW572016 to Treat Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

49

Participants

Timeline

Start Date

August 31, 2004

Primary Completion Date

June 30, 2011

Study Completion Date

February 29, 2012

Conditions
Breast Cancer
Interventions
DRUG

GW572016

Lapatinib, 500 mg

DRUG

lapatinib

Lapatinib 500 mg PO

Trial Locations (3)

77030

Baylor Breast Center, Houston

87131

University of New Mexico, Albuquerque

90033

USC Norris Comprehensive Cancer Center, Los Angeles

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

lead

Baylor Breast Care Center

OTHER

NCT00206427 - Neoadjuvant GW572016 to Treat Breast Cancer | Biotech Hunter | Biotech Hunter